View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 14, 2022updated 11 Jul 2022 1:54pm

Ideaya, Pfizer extend partnership for darovasertib-crizotinib cancer trials

The combination therapy will be analysed in Phase I and Phase II trials for MUM and cMET-driven tumours, respectively.

Ideaya Biosciences and Pfizer have signed clinical trial partnership and supply agreements to assess darovasertib and crizotinib combination treatment in two trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Darovasertib is an inhibitor of protein kinase C (PKC) while crizotinib is a c-mesenchymal-epithelial transition factor (cMET) inhibitor.

The companies will analyse the combination therapy in a Phase II potential registration-enabling trial that will enrol metastatic uveal melanoma (MUM) patients.

Another Phase I trial will assess darovasertib plus crizotinib in individuals with cMET-driven tumours, such as hepatocellular carcinoma (HCC) and/or non-small cell lung cancer (NSCLC). 

Presently, Ideaya is analysing darovasertib and crizotinib combination in an ongoing Phase I/II clinical trial enrolling individuals with MUM and those with GNAQ or GNA11 mutant skin melanoma.

This Phase I/II trial is being carried out under a clinical trial partnership and supply agreement between Pfizer and Ideaya. 

Ideaya anticipates providing results, including tolerability and clinical efficacy, from the Phase I/II trial of the combination therapy in MUM patients in the middle of this year.  

During the same period, the company also intends to seek regulatory advice from the US Food and Drug Administration (FDA) for a potential registration-enabling study design to assess darovasertib plus crizotinib for MUM.

Maturity of data, including necessary interim evaluations of supportive median duration of response and/or median progression-free survival, could impact the reporting of the clinical data and FDA regulatory guidance.

Ideaya Biosciences senior vice-president and chief scientific officer Michael White said: “The clinical efficacy of the combination therapy in MUM patients provides proof of concept for potential expansion opportunities in other cMET-driven tumours. 

“We believe that the darovasertib and crizotinib combination therapy can potentially improve on current standard of care treatment paradigms, for example in HCC, where response rates are modest.”

According to initial clinical data reported in December last year, darovasertib plus crizotinib demonstrated to possess strong clinical activity with a manageable side effect profile for MUM.

In April last year, Ideaya dosed the first subject in Phase I trial of IDE397 to treat methylthioadenosine phosphorylase deletion solid tumours.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena